European Commission Clears Johnson & Johnson’s IMAAVY
Johnson & Johnson has secured European Commission (EC) approval for nipocalimab, to be marketed as IMAAVY, as an add-on therapy for people living with generalised myasthenia gravis (gMG).
The decision marks a significant milestone in neuromuscular disease care, making nipocalimab the first neonatal Fc receptor (FcRn) blocker authorised in Europe for both adults and adolescents aged 12 years and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody-positive.
Generalised myasthenia gravis is a chronic autoimmune condition that disrupts the way nerves communicate with muscles, leading to fluctuating muscle weakness. For many, everyday activities such as chewing, swallowing, speaking, walking or even breathing can become difficult and unpredictable.
Anti-AChR and anti-MuSK antibody-positive patients represent around 90% of the gMG population, meaning the new approval is relevant to the vast majority of those diagnosed with the disease across Europe.
Nipocalimab works by selectively reducing levels of immunoglobulin G (IgG), the class of antibodies that play a central role in driving the autoimmune attack in gMG. By targeting IgG while leaving other parts of the immune system intact, the therapy is designed to address a root cause of the disease without broadly suppressing immune function.
This mechanism aligns with a new generation of precision immunology approaches that aim to deliver more effective symptom control with a carefully managed safety profile.
Clinicians have welcomed the decision as a meaningful expansion of treatment options. Charité – Universitätsmedizin in Berlin noted that with the approval of nipocalimab, they now have an important new treatment choice for a broad range of antibody-positive people living with generalised myasthenia gravis, including adolescents as well as adults.
The centre described the authorisation as a major advance in therapeutic strategies aimed at improving symptom control and supporting long-term disease management in this complex condition.
For patient organisations, the news goes beyond clinical data and speaks to lived experience. The board of the European Myasthenia Gravis Association emphasised that myasthenia gravis is often an “invisible” disease, but its impact is anything but. It can shape every aspect of a person’s life – from independence and education to career prospects, social connections and mental health.
Too often, they noted, the day-to-day struggles of those with gMG go unseen and misunderstood. Against that backdrop, the Association reiterated the need for greater awareness, better resources and stronger support systems so that people living with generalised myasthenia gravis can lead the lives they deserve.
The EC’s decision is underpinned by robust clinical evidence. In the pivotal phase 3 Vivacity-MG3 study, patients receiving nipocalimab in addition to standard care achieved superior disease control compared with those receiving placebo plus standard care.
These improvements were not short-lived: benefits were maintained for up to 20 months in the study’s open-label extension, offering encouraging signs for long-term management. Safety and tolerability findings were consistent with earlier trials, reinforcing confidence in the therapy’s risk–benefit profile.
Experts involved in the clinical development have highlighted the real-world relevance of these data. A professor at the University Federico II of Naples explained that, despite notable advances in treatment over recent years, many people with generalised myasthenia gravis still endure unpredictable symptom fluctuations that can abruptly disrupt daily life.
With strong evidence from both the Vivacity-MG3 and Vibrance-MG studies, nipocalimab now offers an important new option that could help achieve more sustained disease control and provide greater stability for patients managing this challenging condition.
From the industry perspective, the scale of unmet need remains considerable. According to Johnson & Johnson Innovative Medicine EMEA, an estimated 56,000 to 123,000 people across Europe live with generalised myasthenia gravis. For many of them, even simple activities such as breathing or walking can represent a daily challenge.
The company’s Senior Director for the region described the approval of nipocalimab as the first FcRn blocker for a broad population of adults and adolescents with gMG as a meaningful step forward. It is, they noted, an advance aimed at addressing persisting unmet needs and enabling more consistent, long-term disease management.
Final Thoughts
Taken together, the EC approval of nipocalimab as IMAAVY signals a new chapter in the care of generalised myasthenia gravis in Europe.
By pairing a targeted mechanism of action with robust clinical evidence and broad eligibility across both adults and adolescents, the therapy adds a valuable option to a treatment landscape that still leaves many patients struggling with fluctuating, life-limiting symptoms.
For clinicians, patients and advocacy groups alike, the decision offers renewed hope: that more people with gMG will not only gain better control over their disease, but also reclaim more of the independence, stability and quality of life that this invisible yet powerful condition so often undermines.
News Credits: Johnson & Johnson wins EU approval for new gMG treatment
Things you may also like:
- MSD’s Deal Puts Spotlight on hVIVO’s Role in Next-Generation Flu Protection
- eXmoor Pharma and Royal Free London Forge End-to-End Cell and Gene Therapy Pathway
- Alvotech and Advanz Pharma Secure EC Approval for First Simponi Biosimilar Gobivaz